Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 7 studies | 24% ± 4% | |
| epithelial cell | 7 studies | 31% ± 12% | |
| classical monocyte | 6 studies | 26% ± 8% | |
| endothelial cell of artery | 6 studies | 19% ± 2% | |
| ciliated cell | 5 studies | 29% ± 6% | |
| non-classical monocyte | 4 studies | 26% ± 7% | |
| enterocyte | 4 studies | 21% ± 3% | |
| endothelial cell of vascular tree | 4 studies | 19% ± 3% | |
| conventional dendritic cell | 3 studies | 33% ± 12% | |
| vein endothelial cell | 3 studies | 19% ± 3% | |
| glutamatergic neuron | 3 studies | 28% ± 9% | |
| dendritic cell | 3 studies | 39% ± 7% | |
| pancreatic A cell | 3 studies | 19% ± 3% | |
| goblet cell | 3 studies | 21% ± 3% | |
| basal cell | 3 studies | 22% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 2856.52 | 1445 / 1445 | 100% | 63.38 | 183 / 183 |
| intestine | 100% | 3601.79 | 966 / 966 | 100% | 73.35 | 527 / 527 |
| liver | 100% | 3221.52 | 226 / 226 | 100% | 62.31 | 406 / 406 |
| pancreas | 100% | 1628.77 | 328 / 328 | 100% | 49.13 | 178 / 178 |
| stomach | 100% | 2199.43 | 359 / 359 | 100% | 64.17 | 286 / 286 |
| uterus | 100% | 2362.76 | 170 / 170 | 100% | 70.44 | 459 / 459 |
| lung | 100% | 3220.92 | 578 / 578 | 100% | 56.27 | 1154 / 1155 |
| breast | 100% | 3024.69 | 459 / 459 | 100% | 54.07 | 1117 / 1118 |
| bladder | 100% | 2546.48 | 21 / 21 | 100% | 61.64 | 503 / 504 |
| brain | 100% | 2399.33 | 2635 / 2642 | 100% | 48.95 | 705 / 705 |
| prostate | 100% | 2216.60 | 245 / 245 | 100% | 35.00 | 500 / 502 |
| thymus | 100% | 2537.30 | 652 / 653 | 99% | 33.61 | 599 / 605 |
| kidney | 100% | 1699.98 | 89 / 89 | 99% | 31.26 | 888 / 901 |
| adrenal gland | 100% | 1286.39 | 257 / 258 | 97% | 36.57 | 222 / 230 |
| skin | 100% | 4254.39 | 1809 / 1809 | 95% | 27.21 | 450 / 472 |
| ovary | 87% | 933.31 | 156 / 180 | 99% | 35.63 | 427 / 430 |
| adipose | 100% | 3298.82 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 30.70 | 29 / 29 |
| muscle | 100% | 4952.17 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1887.43 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 68.79 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 44.24 | 1 / 1 |
| blood vessel | 100% | 2349.76 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| heart | 99% | 1603.27 | 855 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 71% | 1027.84 | 660 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 59% | 10.39 | 47 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
| GO_0045739 | Biological process | positive regulation of DNA repair |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0001889 | Biological process | liver development |
| GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
| GO_0042267 | Biological process | natural killer cell mediated cytotoxicity |
| GO_0006955 | Biological process | immune response |
| GO_0006351 | Biological process | DNA-templated transcription |
| GO_0016071 | Biological process | mRNA metabolic process |
| GO_0043388 | Biological process | positive regulation of DNA binding |
| GO_0032729 | Biological process | positive regulation of type II interferon production |
| GO_0043353 | Biological process | enucleate erythrocyte differentiation |
| GO_0030183 | Biological process | B cell differentiation |
| GO_0140467 | Biological process | integrated stress response signaling |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
| GO_0000785 | Cellular component | chromatin |
| GO_0005634 | Cellular component | nucleus |
| GO_0003677 | Molecular function | DNA binding |
| GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| GO_0140297 | Molecular function | DNA-binding transcription factor binding |
| GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
| GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
| GO_0043565 | Molecular function | sequence-specific DNA binding |
| GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CEBPG |
| Protein name | CCAAT/enhancer-binding protein gamma (C/EBP gamma) |
| Synonyms | |
| Description | FUNCTION: Transcription factor that binds to the promoter and the enhancer regions of target genes. Binds to the enhancer element PRE-I (positive regulatory element-I) of the IL-4 gene . Binds to the promoter and the enhancer of the immunoglobulin heavy chain. Binds to GPE1, a cis-acting element in the G-CSF gene promoter. . |
| Accessions | P53567 ENST00000652630.1 ENST00000284000.9 ENST00000585933.2 |